DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Diletta Bianchini et al.|The Lancet Oncology|2019Cited by 643
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Johann S. de Bono, Beshara Sheehan et al.|European Urology|2019Cited by 464
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Stephen R. Plymate, Ilsa M. Coleman et al.|Journal of Clinical Investigation|2018Cited by 393